Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study
This randomised feasibility study (n=37) evaluates psilocybin-assisted (microdoses x 6) frontal-midline theta neurofeedback (NF) to improve executive functions (EFs) in participants with psychiatric disorders. Despite no significant improvements in tasks-based EFs, the experimental group reported medium to high gains in daily EFs, indicating the potential benefits of this neuromodulation technique for enhancing daily functioning.
Authors
- Enriquez-Geppert, S,, Lietz, M. P.
- O'Higgins, F.
Published
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting treatment and training responsiveness. In this pioneering study, we evaluated the feasibility and preliminary efficacy of psilocybin-assisted frontal-midline theta neurofeedback (NF), a neuromodulation technique leveraging neuroplasticity, to improve executive functions (EFs). Thirty-seven eligible participants were randomized into an experimental group (n = 18) and a passive control group (n = 19). The experimental group underwent three microdose sessions and then three psilocybin-assisted NF sessions, without requiring psychological support, demonstrating the approach’s feasibility. NF learning showed a statistical trend for increases in frontal-midline theta from session to session with a large effect size and non-significant but medium effect size dynamical changes within sessions. Placebo effects were consistent across groups, with no tasks-based EF improvements, but significant self-reported gains in daily EFs-working memory, shifting, monitoring and inhibition-showing medium and high effect sizes. The experimental group’s significant gains in their key training goals underscored the approach’s external relevance. A thorough study with regular sessions and an active control group is crucial to evaluate EFs improvement and their specificity in future. Psilocybin-enhanced NF could offer significant, lasting benefits across diagnoses, improving daily functioning.
Research Summary of 'Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study'
Introduction
Executive function (EF) deficits are a transdiagnostic problem across psychiatric disorders, impairing everyday functioning and limiting recovery and treatment efficacy. The fronto-cingulo-parietal network underpins EFs, with frontal-midline (fm) theta oscillations (a 4–8 Hz EEG rhythm) implicated as a marker and mediator of top‑down control; higher fm-theta power typically relates to better EF performance. Neurofeedback (NF) trains participants to self‑regulate specific neural signals such as fm-theta and has shown medium-sized effects on components of EF, notably working memory updating, but substantial inter-individual variability and a notable proportion of 'non-responders' limit clinical translation. Impaired neuroplasticity in psychiatric populations may underlie reduced NF responsiveness, and recent preclinical and clinical evidence suggests that serotonergic psychedelics, including psilocybin, act as potent psychoplastogens via 5‑HT2A and TrkB/BDNF-related signalling.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- APA Citation
Enriquez-Geppert, S., Krc, J., O’Higgins, F. J., & Lietz, M. (2024). Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study. Philosophical Transactions of the Royal Society B: Biological Sciences, 379(1915). https://doi.org/10.1098/rstb.2023.0095
References (25)
Papers cited by this study that are also in Blossom
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Kopra, E., Cleare, A. J., Rucker, J. et al. · Journal of Affective Disorders (2022)
Vargas, M. V., Dunlap, L. E., Dong, C. et al. · Science (2023)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · ACS Pharmacology and Translational Science (2020)
Glazer', J., Murray, C. H., Nusslock', R. et al. · Neuropsychopharmacology (2022)
Show all 25 referencesShow fewer
Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Holze, F., Ley, L., Müller, F. et al. · Neuropsychopharmacology (2022)
McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Kiilerich, K. F., Lorenz, J., Scharff, M. B. et al. · Molecular Psychiatry (2023)
Perry, C. M., Malina, M. · Psychopharmacology (2021)
Sanz, C., Cavanna, F., Muller, S. et al. · Psychopharmacology (2022)
Van Elk, M., Fejer, G., Lempe, P. et al. · Psychopharmacology (2021)
Holze, F., Becker, A. M., Kolaczynska, K. E. et al. · Clinical Pharmacology and Therapeutics (2022)
Luethi, D., Hoener, M. C., Krähenbühl, S. et al. · Biochemical Pharmacology (2019)
Vizeli, P., Straumann, I., Holze, F. et al. · Scientific Reports (2021)
Fadiman, J., Korb, S. · Journal of Psychoactive Drugs (2019)
Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.